Plus Therapeutics Inc (PSTV) Actualités

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or...

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

$3.7 Million Private Placement Financing from Existing Investors $2.0 Million Funding Advance from the Cancer...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid...